This Persistence Market Research (PMR) report examines the ‘Asia Pacific Alopecia Treatment Market’ for the period 2016 - 2024. The primary objective of the report is to offer updates and information related to market opportunities in the Asia Pacific alopecia treatment market.
The primary objective of the report is to offer insights into the developments in the alopecia treatment market that are significantly transforming global businesses and enterprises.
Increasing demand for effective hair loss therapies such as stem cell therapy and cytokine therapy is expected to bolster the growth of the alopecia treatment market over the next five years. In addition, increasing focus on providing hair loss solutions with multifunctional effects and larger focus on development of effective hair loss solutions with minimal side effects is expected to drive growth of the alopecia treatment market during the forecast period. Primary demand for hair loss products emerges from developed pharmaceuticals markets such as China and Japan, owing to large base of population with alopecia and presence of companies with highly developed and technically advanced drug manufacturing infrastructure.
The alopecia treatment market report begins with an overview of types of alopecia and various therapies used in its treatment. This section includes identifying the key functions of various hair loss treatment therapies and the respective considerations in each segment for appropriate sizing of the market. The following section underlines factors influencing growth of the alopecia treatment market, along with details of the key trends, drivers, restraints, opportunities, and an analysis on impacts expected to be created by each of the drivers and restraints over the forecast period. Impact analysis of key regional growth drivers and restraints have been assessed based on a weighted average factor model along with key region-specific trends. This has been included in the alopecia treatment market report to better equip clients with information and hidden insights. At the end of the report, PMR has provided an exclusive section on key strategic considerations for a new entrant planning to enter the hair loss treatments in near term. The section highlights key requirements, to better capture higher market share and emerge sustainably profitable over the long term.
The global alopecia treatment market is analysed by type of alopecia; segmented into alopecia areata, alopecia totalis, and alopecia. Based on treatment type; the market has been segmented into topical drugs (creams, oils, lotions, gels, shampoos, and foam), oral drugs, injectable (platelet rich plasma therapy, steroid and injectable fillers), hair transplant services, and low level laser therapy. By end user segment, the market has been segmented into hospitals, dermatology and trichology clinics, home care settings, and aesthetic clinics. A detailed analysis of every segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market attractive index, and BPS analysis has been provided along with appropriate rationale.
The following section of the report highlights the growth trends witnessed in the alopecia treatment market, by country. It provides a market outlook for 2016–2024 and sets the forecast within the context of the alopecia treatment market. The study discusses key regional trends contributing to growth of the alopecia treatment market in Asia Pacific, as well as analyses the extent to which the corresponding drivers are influencing this market in each region currently. Various countries assessed in this report include China, Japan, Australia & New Zealand, Malaysia, Singapore, India, Vietnam, Philippines and Rest of Asia Pacific.
Analysis by type of alopecia, treatment type, end user, and countries helps in evaluating the present scenario and growth prospects of the alopecia treatment market for the period 2016–2024. We have considered 2015 as the base year and provided data for the forecast period.
To ascertain the alopecia treatment market size, we have also considered key quality assessment parameters that should be considered while judging the quality of various hair loss treatment products. The forecast presented here assesses the total revenue generated, by value, across the alopecia treatment market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the alopecia treatment market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of the three different types of analysis, based on supply side, downstream industry demand, and the economic envelope.
In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse based on key parameters, such as Year-on-Year (Y-o-Y) growth rates, to understand the predictability of the market and identify the right opportunities in the alopecia treatment market.
The alopecia treatment segments have been analysed in terms of the Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the alopecia treatment market.
Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources, from a sales and delivery perspective, in the alopecia treatment market.
To understand key growth areas of alopecia treatment in the near future, Persistence Market Research developed the alopecia treatment market’s ‘Attractiveness Index’, which has been represented by for all four categories, chemistry type, application type, functionalities, and regions. The resulting index is expected to help providers identify real market opportunities.
In the final section of the report, information related to the alopecia treatment ‘Strategic Recommendation’ is included to provide report companies with insights required while entering a specific segment or a country to strengthen their revenue footprints in the alopecia treatment market and to differentiate themselves. Key categories of providers covered in the report are alopecia treatment manufacturers. Detailed company profiles have been primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a key market segment in the alopecia treatment value chain, and the potential players with respect to the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on the in-depth assessment of their capabilities and success in the alopecia treatment marketplace.
Detailed profiles of the providers also include company-specific long- and short-term strategies, key offerings, and recent developments in the alopecia treatment market.
Key competitors in the market, covered in terms of manufacturers, include Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science & Technology Co., Ltd.
Key Segments Covered
By Type of Alopecia
By Treatment Type
By End User
Alopecia is a prevalent autoimmune disorder, resulting in loss of hair all over the body, predominantly on the scalp. It usually starts with one or smaller round patches on the scalp (alopecia areata) and progresses to total scalp hair loss (alopecia totalis), or complete body hair loss (alopecia universalis). Alopecia universalis is the least prevalent autoimmune disorder, affecting less than 5% of total population with alopecia. The management of extensive alopecia is challenging and sometimes patients may not respond to therapy. The most common prescribed medication for hair regrowth includes anti-inflammatory medications including topical and intraleisonal corticosteroid injections. Topical 2% and 5% minoxidil solution, and oral finasteride (such as propecia manufactured by Merck and Co. Inc.) is also recommended in treatment of hair loss. The Asia Pacific market for alopecia treatment has been segmented based on treatment type as topical drugs, oral drugs, injectable, hair transplant services, and low level laser therapy. The market has also been segmented by type of alopecia, by end user, and by country.
The Asia Pacific alopecia treatment market is estimated to be valued at US$ 2,665.9 Mn by 2024 end, with various markets registering significant CAGRs during the forecast period.
Growth of the alopecia treatment market is mainly driven by increasing demand for hair loss treatment drugs with enhanced effectiveness and minimal side effects. For example, in recent years cytokine therapy as well regenerative cell therapy is gaining popularity for treatment of various types of alopecia. Treatment with cytokine therapy possess extended ability in hair regrowth resulting in hair follicle cells to get differenced and proliferated while controlling hair growth cycle. Additionally, combination therapies have also demonstrated its clinical efficacy in treatment of alopecia. Combination therapeutics is currently the widest adopted treatment for hair loss management across the Asia Pacific region. Various combination of drugs are being tried by physicians for increasing the effectiveness of treatment of all kinds of alopecia. However, patent expiry of many blockbuster drugs and side effects associated with the available hair loss treatment therapies are expected to hamper the overall market growth hair loss treatments.
Increasing penetration of advanced hair loss treatment therapies, such as stem cell therapy and increased focus on providing hair loss solutions (with both functional and active ingredients) with multifunctional effects is set to define the market landscape of the hair loss industry over the forecast period.
Based on type of alopecia, the market has been segmented into alopecia areata, alopecia totalis, and alopecia universalis. In Asia Pacific, prevalence of alopecia areata has been growing significantly over the years attributed to increasing prevalence of various dermatology related skin disorders. In terms of value, alopecia areata segment is estimated to account for close to one-third of the total market share by 2024 end. The segment is expected to gain market attractiveness throughout the forecast period.
Based on treatment type, the market has been segmented into topical drugs, oral drugs, injectable, hair transplant services, and low level laser therapy. Topical drugs includes creams, gels, lotions, shampoos, and foam, while the injectable treatment type segment includes platelet rich plasma therapy, steroids, and injectable fillers. Propecia, an oral medicines (generic is finasteride) is currently the only FDA approved medicine in treatment of alopecia. Limited clinical efficacy demonstrated by such treatments would hamper market share and revenue growth of established products over the forecast period.
Based on end user, the Asia Pacific alopecia treatment market has been segmented into hospitals, dermatology and trichology clinics, home care settings, and aesthetic clinics. Dermatology and trichology clinics segment is the highest revenue contributor to the Asia Pacific alopecia treatment market followed by home care settings and end user segments. Over the counter distribution and high level of e-Commerce adoption is expected to lead to increased adoption of topical hair loss treatments in home care settings. The segment is expected to be valued at US$ 656.9 Mn by 2024 end, registering a significant CAGR over the forecast period.
The Asia Pacific alopecia treatment market has been segmented into nine major countries namely China, Japan, Australia & New Zealand, Malaysia, Singapore, India, Vietnam, Philippines and Rest of Asia Pacific. In terms of value, China is estimated to be the dominant market for alopecia treatment, accounting US$ 961.3 Mn of the total alopecia treatment market value by 2024 end. India is estimated to emerge as the fastest growing market among all the emerging regions, while revenue from the market in Vietnam is expected to expand at a healthy CAGR of 5.2% over the forecast period despite the ongoing economic downturn in the region.
Some of the key players covered in the alopecia treatment market report are Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science & Technology Co., Ltd. The report is enriched through identification of company-specific strategies related to various hair loss treatments, research and development, market consolidation initiatives, and analyses of the various market player’s specific strengths, weaknesses, opportunities, and threats.